Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Lung Cancer ; 137: 14-18, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31521977

RESUMO

OBJECTIVES: Recent observations indicate a potential survival benefit in patients with malignant pleural effusion (MPE) who achieve successful pleurodesis in comparison to patients who experience effusion recurrence post pleurodesis. This study aimed to explore this observation using two datasets of patients with MPE undergoing talc pleurodesis. MATERIALS AND METHODS: Dataset 1 comprised patients who underwent talc pleurodesis at Oxford Pleural Unit for MPE. Dataset 2 comprised patients enrolled in the TIME1 clinical trial. Pleurodesis success was defined as absence of need for further therapeutic procedures for MPE in the three months following pleurodesis. Data on various clinical, laboratory and radiological parameters were collected and survival was compared according to pleurodesis outcome (success vs. failure) after adjusting for the aforementioned parameters. RESULTS: Dataset 1 comprised 60 patients with mean age 74.1±10.3 years. The most common primary malignancies were mesothelioma, breast and lung cancer. 29 patients (48.3%) achieved pleurodesis. The adjusted odds ratio (aOR) for poor survival with pleurodesis failure was 2.85 (95% CI 1.08-7.50, =p 0.034). Dataset 2 comprised 259 patients from the TIME1 trial. The mean age was 70.8±10.3 and the most common primary malignancies were mesothelioma, lung and breast cancer. Pleurodesis was successful in 205 patients (79%). aOR for poor survival was 1.62 (95% CI 1.09-2.39, p = 0.015). CONCLUSION: Achieving pleurodesis seems to impart a survival benefit in patients with MPE. Further studies are required to explore factors that may contribute to this phenomenon and to address the difference in survival between pleurodesis and indwelling pleural catheter interventions.


Assuntos
Antiperspirantes/farmacologia , Neoplasias Pulmonares/mortalidade , Mesotelioma/mortalidade , Derrame Pleural Maligno/mortalidade , Pleurodese/mortalidade , Talco/farmacologia , Idoso , Feminino , Seguimentos , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Mesotelioma/tratamento farmacológico , Mesotelioma/patologia , Mesotelioma Maligno , Derrame Pleural Maligno/tratamento farmacológico , Derrame Pleural Maligno/patologia , Prognóstico , Taxa de Sobrevida
3.
Breathe (Sheff) ; 13(3): 247-249, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28894489

RESUMO

In Egypt, respiratory medicine (more commonly termed "chest diseases") is regarded as a separate speciality rather than a subspecialty of internal medicine. All graduates of Egyptian Medical Schools have to complete a year of internship at teaching hospitals rotating between different medical and surgical departments. Following internship and obtaining licence to practice, doctors are required to work for 6-12 months at primary healthcare facilities around the country. At the end of this period, a doctor can start their specialty training; the choice of which depends on the cumulative score they achieved at medical school.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...